Trial Profile
A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged with Influenza A/Perth/16/2009(H3N2) Virus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors hVIVO
- 06 Jun 2017 New trial record
- 25 Apr 2017 Data from this study published in a hVIVO Media Release.